Chromophobe Renal Cell Carcinoma
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
HNF1A,
HNF1B,
TP53,
PTEN,
FLCN,
PIK3CA,
VHL,
ERBB2,
TFE3,
SLC2A1,
KRT7,
PBRM1,
PRCC,
PIDD1,
RYR1,
SFRP2,
RELA,
PVALB,
PTGS2,
ACHE,
BIRC7,
SLC5A3,
MUC4,
LDHB,
AHNAK,
M6PR,
MET,
MITF,
SPTBN4,
NF2
HNF1A,
HNF1B,
TP53,
PTEN,
FLCN,
PIK3CA,
VHL,
ERBB2,
TFE3,
SLC2A1,
KRT7,
PBRM1,
PRCC,
PIDD1,
RYR1,
SFRP2,
RELA,
PVALB,
PTGS2,
ACHE,
BIRC7,
SLC5A3,
MUC4,
LDHB,
AHNAK,
M6PR,
MET,
MITF,
SPTBN4,
NF2,
AP5M1,
OGG1,
PEBP1,
PAK1,
PDHB,
FMN2,
PGK1,
POMC,
ELOC,
SOD2,
ADIPOQ,
PRAME,
SETD2,
SYNE2,
PDXDC1,
RNF139,
AKAP13,
BTG3,
CPQ,
NDRG1,
CUL7,
KEAP1,
ZNF536,
SHANK1,
RPL14,
TET2,
INPP4B,
FPGT,
TNFSF10,
CRADD,
UNC5C,
TAGLN2,
BAP1,
KDM5C,
MLLT10,
LRP1B,
TSC1,
TGM2,
L1CAM,
YIPF3,
PNKD,
KRT32,
SCARB1,
EPAS1,
KRT8,
ASB15,
DNHD1,
EEF2,
FAAH2,
DAPK1,
CTSD,
CTSB,
CRYAB,
CRABP1,
OR4C13,
CNN2,
VMO1,
MSGN1,
ZNF804A,
FAM111B,
CASP2,
CAPG,
BCHE,
APRT,
BIRC5,
APAF1,
ANXA4,
ALOX12B,
ALOX5,
ALK,
ALDH1A1,
ALAD,
ACY1,
CSMD3,
LRRK2,
HSPB1,
GSTT1,
IL13,
IL6R,
IL6,
IL4R,
KCNMA1,
IFNA2,
HSPD1,
FLT1,
HSPA9,
LMAN2L,
HARS1,
CARD11,
GJB1,
GSTP1,
NLRP12,
MTOR,
GSTM1,
SLC49A4,
GRB7,
ZNF765,
NAV3,
HNF1A-AS1,
KIT,
S100A1,
CCND1,
HTC2,
PDCD1LG2,
CD82,
HES4,
CDC73,
ERCC6L,
MIR21,
MIR141,
PSAT1,
SCHIP1,
BHD,
ACAT1,
PROS1,
SMUG1,
SF3B1,
GGT1,
FUT4,
FOLH1,
FOXI1,
ERBB4,
ENPEP,
ELF3,
ELAVL2,
EDNRB,
ACE,
CLDN7,
CP,
CDH16,
CAV1,
CASP3,
KLK3,
ANPEP,
NR3C1,
HIF1A,
HOXA9,
SDHB,
NPEPPS,
NAPSA,
COX5A,
BSND,
TWIST1,
ADAM17,
SLC4A1,
SDC1,
ITGAV,
PLAG1,
SLC26A4,
MST1R,
LGALS3,
LEP,
LAMP1,
KLK2,
CD24
Drugs
(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate,
26 base single stranded phosphodiester DNA oligonucleotide,
4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline
(R, S)-3-(bromomethyl)-3-butanol-1-yl-diphosphate,
26 base single stranded phosphodiester DNA oligonucleotide,
4-amino-5-oxo-4 (pyridinium-1-ylmethyl) proline,
Aldesleukin
(
PROLEUKIN
),
Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex
(
ONCOPHAGE
),
Autologous renal cell tumor vaccine,
Axitinib
(
INLYTA
),
Bevacizumab
(
Equidacent,
AVASTIN,
Aybintio,
MVASI
),
Everolimus
(
AFINITOR,
VOTUBIA
),
Genetically modified allogeneic (human) tumour cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM),
Girentuximab
(
RENCAREX
),
HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMPMMPMUC-RGS),
Human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and nonglycosylated) (inhalation use),
Humanized anti-KSA monoclonal antibody-human interleukin-2 fusion protein,
Interferon gamma 1b
(
ACTIMMUNE,
IMUKIN
),
Iodine (131I) chimeric IgG monoclonal antibody cG250,
N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate,
Naptumomab estafenatox,
Pazopanib hydrochloride
(
VOTRIENT
),
Recombinant human interleukin-21,
Recombinant modified vaccinia Ankara expressing human 5T4,
Siltuximab
(
SYLVANT
),
Sorafenib tosylate
(
NEXAVAR
),
Sunitinib malate
(
SUTENT
),
Talactoferrinum alfa,
Temsirolimus
(
TORISEL
)
Registered!
Chromophobe renal cell carcinoma is a rare subtype of renal cell carcinoma, originating from the intercalating cells of the collecting ducts and macroscopically manifesting as a well-circumscribed, highly lobulated, solid tumor that is usually diagnosed at an early stage. It is frequently asymptomatic, or may present with nonspecific symptoms, such as weight loss, fever or fatigue. The classic presentation observed in renal tumors (hematuria, flank pain and palpable mass) is occasionally observed and usually indicates an advanced stage of the disease. It is most frequently sporadic however, several familial cases, associated with Birt-Hogg Dubé syndrome, have been described.